Fusion Pharmaceuticals - FUSN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.80
  • Forecasted Upside: 4.94%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$13.15
▼ -0.31 (-2.30%)

This chart shows the closing price for FUSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FUSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FUSN

Analyst Price Target is $13.80
▲ +4.94% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Fusion Pharmaceuticals in the last 3 months. The average price target is $13.80, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 4.94% upside from the last price of $13.15.

This chart shows the closing price for FUSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Fusion Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00Low
1/5/2024Bloom BurtonReiterated RatingBuyLow
1/5/2024William BlairReiterated RatingOutperformLow
1/5/2024OppenheimerBoost TargetOutperform ➝ Outperform$13.00 ➝ $15.00Low
1/5/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$15.00 ➝ $16.00Low
1/2/2024WedbushReiterated RatingOutperform$13.00Low
12/27/2023OppenheimerReiterated RatingOutperform ➝ Outperform$13.00Low
12/27/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$12.00 ➝ $15.00Low
12/20/2023Royal Bank of CanadaInitiated CoverageOutperform$12.00Low
11/7/2023WedbushReiterated RatingOutperform$13.00Low
10/3/2023B. RileyReiterated RatingBuy ➝ Buy$13.00Low
9/28/2023OppenheimerInitiated CoverageOutperform$13.00Low
8/28/2023Raymond JamesLower TargetOutperform ➝ Outperform$13.00 ➝ $12.00Low
6/23/2023Raymond JamesInitiated CoverageOutperform$13.00Low
3/30/2023B. RileyReiterated RatingBuy$10.00Low
2/13/2023Brookline Capital ManagementReiterated RatingBuyLow
1/27/2023Morgan StanleyLower TargetOverweight$19.00 ➝ $10.00Low
12/1/2022B. RileyReiterated RatingBuy$10.00N/A
11/30/2022SVB LeerinkInitiated CoverageOutperform$6.00Low
9/15/2022Truist FinancialInitiated CoverageBuyLow
9/6/2022JonestradingInitiated CoverageBuyLow
7/6/2022William BlairInitiated CoverageOutperform ➝ OutperformN/A
5/10/2022WedbushLower TargetOutperform$20.00 ➝ $19.00High
2/2/2022Brookline Capital ManagementReiterated RatingBuyMedium
11/25/2021B. RileyReiterated RatingBuy$17.00Low
8/26/2021B. RileyInitiated CoverageBuy$17.00Medium
8/18/2021Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00High
8/10/2021WedbushReiterated RatingOutperformMedium
5/18/2021Morgan StanleyLower TargetOverweight$21.00 ➝ $20.00Low
4/6/2021Morgan StanleyLower TargetOverweight$23.00 ➝ $21.00Low
12/17/2020Bloom BurtonReiterated RatingBuyMedium
7/21/2020Morgan StanleyInitiated CoverageOverweight$23.00High
7/21/2020Jefferies Financial GroupInitiated CoverageBuy$25.00High
7/21/2020WedbushInitiated CoverageOutperform$25.00High
7/21/2020CowenInitiated CoverageOutperformHigh
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/21/2024

Current Sentiment

  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Fusion Pharmaceuticals logo
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Read More

Today's Range

Now: $13.15
Low: $13.10
High: $13.99

50 Day Range

MA: $9.43
Low: $5.25
High: $13.46

52 Week Range

Now: $13.15
Low: $2.31
High: $13.99

Volume

473,353 shs

Average Volume

1,291,558 shs

Market Capitalization

$952.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fusion Pharmaceuticals?

The following equities research analysts have issued stock ratings on Fusion Pharmaceuticals in the last twelve months: B. Riley, Bloom Burton, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Wedbush, and William Blair.
View the latest analyst ratings for FUSN.

What is the current price target for Fusion Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Fusion Pharmaceuticals in the last year. Their average twelve-month price target is $13.80, suggesting a possible upside of 4.9%. Raymond James has the highest price target set, predicting FUSN will reach $16.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $12.00 for Fusion Pharmaceuticals in the next year.
View the latest price targets for FUSN.

What is the current consensus analyst rating for Fusion Pharmaceuticals?

Fusion Pharmaceuticals currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FUSN will outperform the market and that investors should add to their positions of Fusion Pharmaceuticals.
View the latest ratings for FUSN.

What other companies compete with Fusion Pharmaceuticals?

How do I contact Fusion Pharmaceuticals' investor relations team?

Fusion Pharmaceuticals' physical mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company's listed phone number is 289-799-0891 and its investor relations email address is [email protected]. The official website for Fusion Pharmaceuticals is fusionpharma.com. Learn More about contacing Fusion Pharmaceuticals investor relations.